The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models.
William R. Moore
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Sankar N. Maity
No relevant relationships to disclose
Joel Robert Eisner
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Edward P. Garvey
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
William J. Hoekstra
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Mark Anton Titus
No relevant relationships to disclose
Christopher Logothetis
No relevant relationships to disclose
John C. Araujo
No relevant relationships to disclose
Eleni Efstathiou
No relevant relationships to disclose
Robert J. Schotzinger
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals